Abstract
Multisystem inflammatory syndrome in children (MIS-C) is an entity in which children develop fever, raised inflammatory parameters, abdominal complaints and/or Kawasaki-like symptoms with signs of decreased cardiac function, weeks after a primary infection by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Complications include shock and coronary artery aneurysms. Our cases are in line with current evidence that clinical presentation of MIS-C is extremely variable, and evolution is favourable after treatment with intravenous immunoglobulins. Further research is necessary to substantiate current guidelines and to analyse possible links we have encountered between developing MIS-C and ethnic background, environment, and specific SARS-CoV-2 strains.